Aynalem SB, Zeleke AJ. Prevalence of Diabetes Mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman Town, Southwest Ethiopia, 2016: a cross sectional study. Int J Endocrinol. 2018;2018:9317987. https://doi.org/10.1155/2018/9317987.

Article  PubMed  PubMed Central  Google Scholar 

Diabetes [Internet]. [cited 2023 Dec 19]. Available from: https://www.who.int/health-topics/diabetes#tab=tab_1. Accessed 11 Dec 2023

Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9:525–44. https://doi.org/10.1016/S2213-8587(21)00113-3.

Article  CAS  PubMed  Google Scholar 

Ng E, Shaw JE, Wood A, Maple-Brown LJ, Hare MJ. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes. Aust J Gen Pract. 2022;51:513–8. https://doi.org/10.31128/AJGP-07-21-6057.

Article  PubMed  Google Scholar 

Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021;12:721135. https://doi.org/10.3389/fendo.2021.721135.

Article  PubMed  Google Scholar 

Pratama KG, Tandarto K, Hengky A. Weight loss effect of sodium-glucose, cotransporter-2 (sglt2) inhibitors in patients with obesity without diabetes: a systematic review. Acta Endocrinol (Buchar). 2022;18(2):216–24. https://doi.org/10.4183/aeb.2022.216.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, et al. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care. 2022;10:e002207.

Article  PubMed  PubMed Central  Google Scholar 

Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, et al. Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study. Diabetes Obes Metab. 2019;21:2429–39. https://doi.org/10.1111/dom.13824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoon K, Kang J, Kwon SC, Trautmann ME, Hompesch M, Stewart J, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22:1292–301. https://doi.org/10.1111/dom.14032.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdelhaleem IA, Abd-Elhamied MA, Morsi AE, Kenawy S. Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2022;24:555–60. https://doi.org/10.1111/dom.14602.

Article  CAS  PubMed  Google Scholar 

Escobar J, Monday O, Vemoori Y, et al. Safety and efficacy of Efpeglenatide in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Cureus. 2023;15(9):e45927. https://doi.org/10.7759/cureus.45927.

Ansari HUH, Qazi SU, Sajid F, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024;30(2):160–71. https://doi.org/10.1016/j.eprac.2023.11.007.

Article  PubMed  Google Scholar 

Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:1–12. https://doi.org/10.1155/2018/4020492.

Article  CAS  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89. https://doi.org/10.1136/bmj.n71.

Article  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR et al. 2. Classification and diagnosis of diabetes: Standards of care in diabetes-2023 [published correction appears in Diabetes Care. 2023;:] [published correction appears in Diabetes Care. 2023;46(9):1715]. Diabetes Care. 2023;46(Suppl 1):S19-S40. https://doi.org/10.2337/dc23-S002

Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928-5928. https://doi.org/10.1136/bmj.d5928.

Article  PubMed  PubMed Central  Google Scholar 

Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2023 Dec 2]. Available from: https://training.cochrane.org/handbook

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. https://doi.org/10.1111/j.0006-341x.2000.00455.x.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Li Z, Ramasundarahettige C, Baek S, Branch KRH, Del Prato S, et al. Exploring the relationship between Efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial. Circulation. 2023;147:1004–13. https://doi.org/10.1161/CIRCULATIONAHA.122.063716.

Article  CAS  PubMed  Google Scholar 

Del Prato S, Kang J, Trautmann ME, Stewart J, Sorli CH, Derwahl M, et al. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Diabetes Obes Metab. 2020;22:1176–86. https://doi.org/10.1111/dom.14020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, et al. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase ib study. BMJ Open Diabetes Res Care. 2021;9:e002208.

Article  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, et al. Once-weekly Efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to Liraglutide. Diabetes Care. 2019;42:1733–41. https://doi.org/10.2337/dc18-2648.

Article  CAS  PubMed  Google Scholar 

Aroda VR, Frias JP, Ji L, Niemoeller E, Nguyên-Pascal M-L, Denkel K, et al. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials. Diabetes Obes Metab. 2023;25:2084–95. https://doi.org/10.1111/dom.15079.

Article  CAS  PubMed  Google Scholar 

Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al. Efficacy and safety of once-weekly Efpeglenatide Monotherapy Versus Placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45:1592–600. https://doi.org/10.2337/dc21-2656.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose Cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145:565–74. https://doi.org/10.1161/CIRCULATIONAHA.121.057934.

Article  CAS  PubMed  Google Scholar 

McCormack JP, Allan GM, Virani AS. Is bigger better? An argument for very low starting doses. CMAJ. 2011;183(1):65–9. https://doi.org/10.1503/cmaj.091481.

Article  PubMed  PubMed Central  Google Scholar 

Tariq MA, Amin H, Shurjeel Q, Gang A, Mohiuddin A. Gastrointestinal adverse events of semaglutide in patients with overweight or obesity. Eur J Intern Med. 2022;106:138–9. https://doi.org/10.1016/j.ejim.2022.08.015.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/NEJMoa2307563.

Article  CAS  PubMed  Google Scholar